7/9/2014 11:12:24 AM
CAMBRIDGE, England--(BUSINESS WIRE)--Biosceptre International Limited, the oncology company developing antibody products that target the nf-P2X7 receptor, today announced that it has raised AU$5m through a syndicate of existing investors. The funds raised will enable the Company to progress the lead systemic programme, BIL-221s through Phase I development.
Help employers find you! Check out all the jobs and post your resume.
comments powered by